Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray

Authors: Jiehua He, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, Guinan Lin, Xiaomei Jiang, Tao Qin

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

The aim of this study is to analyze the prognostic value of androgen receptor (AR) expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for AR was performed on tissue microarrays of operable breast cancer from 287 patients with TNBC, who were treated at Sun Yat-sen University Cancer Center from January 1995 to December 2008. AR expression was found in 25.8% of the cases with TNBC. TNBC patients with AR negative have a higher proportion of positive lymph node. A significant correlation was found between AR expression and disease-free survival (DFS) and overall survival (OS). Univariated analysis indicated that AR expression had a significant prognostic value in TNBC patients, whereas multivariate analysis indicated that AR was a significant independent prognostic factor of DFS (P = 0.032) in all patients. Our results suggested that AR was a favorable prognostic factor of DFS and OS in patients with TNBC. Therefore, TNBC may be further divided into two subtypes according to AR status.
Literature
1.
go back to reference Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.PubMedCrossRef
2.
go back to reference Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.PubMedCrossRef Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.PubMedCrossRef
3.
go back to reference Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.PubMedCrossRef
4.
go back to reference Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109:1721–8.PubMedCrossRef Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer. 2007;109:1721–8.PubMedCrossRef
5.
go back to reference Hines SL, et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008;19(9):1561–5.PubMedCrossRef Hines SL, et al. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008;19(9):1561–5.PubMedCrossRef
6.
go back to reference Lin Nu, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.PubMedCrossRef Lin Nu, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–45.PubMedCrossRef
7.
go back to reference Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Br Cancer Res. 2008;10(1):R20.CrossRef Nam BH, et al. Breast cancer subtypes and survival in patients with brain metastases. Br Cancer Res. 2008;10(1):R20.CrossRef
8.
go back to reference Schneider BP, et al. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.PubMedCrossRef Schneider BP, et al. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8.PubMedCrossRef
9.
go back to reference Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000;6:433–8.PubMed Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit. 2000;6:433–8.PubMed
10.
go back to reference Liao DJ, et al. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;20:175–89.CrossRef Liao DJ, et al. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;20:175–89.CrossRef
11.
go back to reference Hankinson SE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–9.PubMedCrossRef Hankinson SE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–9.PubMedCrossRef
12.
go back to reference Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.PubMedCrossRef Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994–4008.PubMedCrossRef
13.
go back to reference Agoff SN, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725–31.PubMedCrossRef Agoff SN, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120:725–31.PubMedCrossRef
14.
go back to reference Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.PubMedCrossRef Gonzalez-Angulo AM, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15:2472–8.PubMedCrossRef
15.
go back to reference Kononen J, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.PubMedCrossRef Kononen J, et al. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.PubMedCrossRef
Metadata
Title
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray
Authors
Jiehua He
Roujun Peng
Zhongyu Yuan
Shusen Wang
Jiewen Peng
Guinan Lin
Xiaomei Jiang
Tao Qin
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9832-0

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.